Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B

Abstract

Introduction Recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) has been shown to be an effective, well-tolerated treatment for patients with severe hemophilia B who had previously received factor replacement therapy. This study investigated the safety and efficacy of rIX-FP in previously untreated patients (PUPs).

Methods Patients with moderately severe/severe hemophilia B (≤2% FIX) previously untreated with FIX replacement products received rIX-FP (25–75 IU/kg) prophylaxis weekly or on-demand treatment over ≥50 exposure days (EDs). Primary outcomes were the number of patients who developed FIX inhibitors and mean incremental recovery (IR) following a 50 IU/kg dose of rIX-FP. Secondary outcomes included incidence of adverse events (AEs) and annualized bleeding rates (ABRs).

Results In total, 12 PUPs with a median age of 0 years (range, 0–11 years) were treated with rIX-FP for a median of 50 EDs (6/12 prophylaxis; 6/12 on-demand then prophylaxis). Overall, 11/12 patients did not develop FIX inhibitors; one 11-year-old patient developed an inhibitor against FIX after 8 EDs and was ultimately withdrawn. Mean (standard deviation) IR was 1.2 (0.4, n = 8) (IU/dL)/(IU/kg). Of the 137 treatment-emergent AEs recorded, five were attributed to rIX-FP. On the prophylaxis regimen, median ABR was 1.0 (range, 0–3.9, n = 12). No thromboembolic events or deaths occurred during the study.

Conclusion This study provides data to support the safety and efficacy of rIX-FP in PUPs requiring on-demand or prophylactic treatment for moderately severe/severe hemophilia B, consistent with results in previously treated patients. Overall, 1/12 patients developed an inhibitor against FIX.

Keywords

factor IX - hemophilia B - pediatric - previously untreated patients - prophylaxis

Publikationsverlauf

Eingereicht: 14. August 2023

Angenommen: 31. Januar 2024

Artikel online veröffentlicht:
26. März 2024

• References

• 1 Srivastava A, Santagostino E, Dougall A. et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl. 06) 1-158
• 2 Shapiro A, Potts J, Li S. et al. Association of bleeding tendency with time under target FIX activity levels in severe hemophilia B patients treated with recombinant factor IX Fc fusion protein. Blood 2013; 122: 2349
• 3 Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol 2018; 11 (08) 673-683
• 4 Fischer K, Lassila R, Peyvandi F. et al; EUHASS participants. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 2015; 113 (05) 968-975
• 5 Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15 (05) 1027-1031
• 6 European Medicines Agency. Summary of Product Characteristics. IDELVION. 2023. . Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/idelvion
• 7 Kenet G, Chambost H, Male C. et al; PROLONG-9FP Investigator Study Group. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. Thromb Haemost 2016; 116 (04) 659-668
• 8 Kenet G, Chambost H, Male C. et al. Long-term safety and efficacy of recombinant coagulation factor IX albumin fusion protein (rIX-FP) in previously treated pediatric patients with hemophilia B: Results from a phase 3b extension study. Thromb Haemost 2020; 120 (04) 599-606
• 9 Mancuso ME, Lubetsky A, Pan-Petesch B. et al. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost 2020; 18 (05) 1065-1074
• 10 Santagostino E, Negrier C, Klamroth R. et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120 (12) 2405-2411
• 11 Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009; 102 (04) 634-644
• 12 European Medicines Agency. Guidelines on clinical investigation of recombinant and human plasma-derived factor IX products. 2011 . Available at: https://www.ema.europa.eu/en/clinical-investigation-recombinant-and-human-plasma-derived-factor-ix-products-scientific-guideline
• 13 Male C, Andersson NG, Rafowicz A. et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: A PedNet study. Haematologica 2021; 106 (01) 123-129
• 14 Lillicrap D. Evaluating the potential benefits of the extravascular pool of factor IX. Blood Coagul Fibrinolysis 2021; 32 (01) 68-69
• 15 Santagostino E, Martinowitz U, Lissitchkov T. et al; PROLONG-9FP Investigators Study Group. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: Results of a phase 3 trial. Blood 2016; 127 (14) 1761-1769
• 16 Nolan B, Klukowska A, Shapiro A. et al. Final results of the PUPs B-LONG study: Evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Adv 2021; 5 (13) 2732-2739
• 17 Chan AK, Alamelu J, Barnes C. et al. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients. Res Pract Thromb Haemost 2020; 4 (07) 1101-1113